{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T19:56:43Z","timestamp":1771531003545,"version":"3.50.1"},"reference-count":337,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T00:00:00Z","timestamp":1685836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006742","name":"CESPU\u2014Cooperativa de Ensino Superior Polit\u00e9cnico e Univer-sit\u00e1rio Crl","doi-asserted-by":"publisher","award":["AntiMitoSphere_APSFCT_IINFACTS_2021"],"award-info":[{"award-number":["AntiMitoSphere_APSFCT_IINFACTS_2021"]}],"id":[{"id":"10.13039\/501100006742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006742","name":"CESPU\u2014Cooperativa de Ensino Superior Polit\u00e9cnico e Univer-sit\u00e1rio Crl","doi-asserted-by":"publisher","award":["Flav4Tumor-GI2-CESPU-2022"],"award-info":[{"award-number":["Flav4Tumor-GI2-CESPU-2022"]}],"id":[{"id":"10.13039\/501100006742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006742","name":"CESPU\u2014Cooperativa de Ensino Superior Polit\u00e9cnico e Univer-sit\u00e1rio Crl","doi-asserted-by":"publisher","award":["SGA4Cancer-GI2-CESPU-2022"],"award-info":[{"award-number":["SGA4Cancer-GI2-CESPU-2022"]}],"id":[{"id":"10.13039\/501100006742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006742","name":"CESPU\u2014Cooperativa de Ensino Superior Polit\u00e9cnico e Univer-sit\u00e1rio Crl","doi-asserted-by":"publisher","award":["upPTXovcar-GI2-CESPU-2022"],"award-info":[{"award-number":["upPTXovcar-GI2-CESPU-2022"]}],"id":[{"id":"10.13039\/501100006742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006742","name":"CESPU\u2014Cooperativa de Ensino Superior Polit\u00e9cnico e Univer-sit\u00e1rio Crl","doi-asserted-by":"publisher","award":["BD\/CBAS\/CESPU\/01\/2020"],"award-info":[{"award-number":["BD\/CBAS\/CESPU\/01\/2020"]}],"id":[{"id":"10.13039\/501100006742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006742","name":"CESPU\u2014Cooperativa de Ensino Superior Polit\u00e9cnico e Univer-sit\u00e1rio Crl","doi-asserted-by":"publisher","award":["BD\/CBAS\/CESPU\/01\/2021"],"award-info":[{"award-number":["BD\/CBAS\/CESPU\/01\/2021"]}],"id":[{"id":"10.13039\/501100006742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006742","name":"CESPU\u2014Cooperativa de Ensino Superior Polit\u00e9cnico e Univer-sit\u00e1rio Crl","doi-asserted-by":"publisher","award":["2022.09451.BD"],"award-info":[{"award-number":["2022.09451.BD"]}],"id":[{"id":"10.13039\/501100006742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT)","doi-asserted-by":"publisher","award":["AntiMitoSphere_APSFCT_IINFACTS_2021"],"award-info":[{"award-number":["AntiMitoSphere_APSFCT_IINFACTS_2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT)","doi-asserted-by":"publisher","award":["Flav4Tumor-GI2-CESPU-2022"],"award-info":[{"award-number":["Flav4Tumor-GI2-CESPU-2022"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT)","doi-asserted-by":"publisher","award":["SGA4Cancer-GI2-CESPU-2022"],"award-info":[{"award-number":["SGA4Cancer-GI2-CESPU-2022"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT)","doi-asserted-by":"publisher","award":["upPTXovcar-GI2-CESPU-2022"],"award-info":[{"award-number":["upPTXovcar-GI2-CESPU-2022"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT)","doi-asserted-by":"publisher","award":["BD\/CBAS\/CESPU\/01\/2020"],"award-info":[{"award-number":["BD\/CBAS\/CESPU\/01\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT)","doi-asserted-by":"publisher","award":["BD\/CBAS\/CESPU\/01\/2021"],"award-info":[{"award-number":["BD\/CBAS\/CESPU\/01\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT)","doi-asserted-by":"publisher","award":["2022.09451.BD"],"award-info":[{"award-number":["2022.09451.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Oral cancer is a highly aggressive tumor with invasive properties that can lead to metastasis and high mortality rates. Conventional treatment strategies, such as surgery, chemotherapy, and radiation therapy, alone or in combination, are associated with significant side effects. Currently, combination therapy has become the standard practice for the treatment of locally advanced oral cancer, emerging as an effective approach in improving outcomes. In this review, we present an in-depth analysis of the current advancements in combination therapies for oral cancer. The review explores the current therapeutic options and highlights the limitations of monotherapy approaches. It then focuses on combinatorial approaches that target microtubules, as well as various signaling pathway components implicated in oral cancer progression, namely, DNA repair players, the epidermal growth factor receptor, cyclin-dependent kinases, epigenetic readers, and immune checkpoint proteins. The review discusses the rationale behind combining different agents and examines the preclinical and clinical evidence supporting the effectiveness of these combinations, emphasizing their ability to enhance treatment response and overcome drug resistance. Challenges and limitations associated with combination therapy are discussed, including potential toxicity and the need for personalized treatment approaches. A future perspective is also provided to highlight the existing challenges and possible resolutions toward the clinical translation of current oral cancer therapies.<\/jats:p>","DOI":"10.3390\/pharmaceutics15061653","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T01:53:25Z","timestamp":1685930005000},"page":"1653","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Combination Therapy as a Promising Way to Fight Oral Cancer"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4455-4286","authenticated-orcid":false,"given":"Jo\u00e3o P. N.","family":"Silva","sequence":"first","affiliation":[{"name":"UNIPRO\u2014Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Polit\u00e9cnico e Universit\u00e1rio (CESPU), Rua Central de Gandra, 1317, 4585-116 Gandra, Portugal"}]},{"given":"B\u00e1rbara","family":"Pinto","sequence":"additional","affiliation":[{"name":"UNIPRO\u2014Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Polit\u00e9cnico e Universit\u00e1rio (CESPU), Rua Central de Gandra, 1317, 4585-116 Gandra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8938-1297","authenticated-orcid":false,"given":"Lu\u00eds","family":"Monteiro","sequence":"additional","affiliation":[{"name":"UNIPRO\u2014Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Polit\u00e9cnico e Universit\u00e1rio (CESPU), Rua Central de Gandra, 1317, 4585-116 Gandra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0694-7321","authenticated-orcid":false,"given":"Patr\u00edcia M. A.","family":"Silva","sequence":"additional","affiliation":[{"name":"UNIPRO\u2014Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Polit\u00e9cnico e Universit\u00e1rio (CESPU), Rua Central de Gandra, 1317, 4585-116 Gandra, Portugal"},{"name":"TOXRUN\u2014Toxicology Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Polit\u00e9cnico e Universit\u00e1rio (CESPU), Rua Central de Gandra, 1317, 4585-116 Gandra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4006-5779","authenticated-orcid":false,"given":"Hassan","family":"Bousbaa","sequence":"additional","affiliation":[{"name":"UNIPRO\u2014Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Polit\u00e9cnico e Universit\u00e1rio (CESPU), Rua Central de Gandra, 1317, 4585-116 Gandra, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.3747\/co.26.3946","article-title":"Real-World Systemic Therapy Treatment Patterns for Squamous Cell Carcinoma of the Head and Neck in Canada","volume":"26","author":"Byrne","year":"2019","journal-title":"Curr. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101036","DOI":"10.1016\/j.disamonth.2020.101036","article-title":"Novel Therapies in the Management of Oral Cancer: An Update","volume":"66","author":"Nandini","year":"2020","journal-title":"Disease-a-Month"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/jop.12733","article-title":"Perspectives on Oral Squamous Cell Carcinoma Prevention\u2014Proliferation, Position, Progression and Prediction","volume":"47","author":"Thomson","year":"2018","journal-title":"J. Oral Pathol. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"105074","DOI":"10.1016\/j.oraloncology.2020.105074","article-title":"Combinatorial Approaches Targeting the EGFR Family and C-Met in SCCHN","volume":"112","author":"Wang","year":"2021","journal-title":"Oral Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100988","DOI":"10.1016\/j.disamonth.2020.100988","article-title":"Epidemiologic Aspects of Oral Cancer","volume":"66","author":"Sarode","year":"2020","journal-title":"Disease-a-Month"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tsai, W.C., Kung, P.T., Wang, Y.H., Huang, K.H., and Liu, S.A. (2017). Influence of Time Interval from Diagnosis to Treatment on Survival for Oral Cavity Cancer: A Nationwide Cohort Study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0175148"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/hed.25595","article-title":"Survival of Patients with Head and Neck Cancer with Metachronous Multiple Primary Tumors Is Surprisingly Favorable","volume":"41","author":"Bugter","year":"2019","journal-title":"Head Neck"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1080\/21691401.2019.1573176","article-title":"Combinatorial Therapeutic Approach for Treatment of Oral Squamous Cell Carcinoma","volume":"47","author":"Bharadwaj","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Huang, C.H., Huang, T.Y., Chang, W.J., Pan, Y.S., Chu, H.R., Li, Z.L., Unson, S., Chin, Y.T., Lin, C.Y., and Huang, H.M. (2020). Combined Treatment of Heteronemin and Tetrac Induces Antiproliferation in Oral Cancer Cells. Mar. Drugs, 18.","DOI":"10.3390\/md18070348"},{"key":"ref_11","unstructured":"National Cancer Institute (2002). PDQ Adult Treatment Editorial Board Lip and Oral Cavity Cancer Treatment (Adult) (PDQ\u00ae): Health Professional Version."},{"key":"ref_12","first-page":"1181","article-title":"Chemosensitization of Oral Squamous Cell Carcinoma Cells to Cisplatin by Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid","volume":"30","author":"Rikiishi","year":"2007","journal-title":"Int. J. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.phymed.2016.09.005","article-title":"Copper Supplementation Amplifies the Anti-Tumor Effect of Curcumin in Oral Cancer Cells","volume":"23","author":"Lee","year":"2016","journal-title":"Phytomedicine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.trci.2017.10.005","article-title":"Drug Discovery and Development: Role of Basic Biological Research","volume":"3","author":"Mohs","year":"2017","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination Therapy in Combating Cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-cancerbio-042716-094839","article-title":"Resisting Resistance","volume":"1","author":"Bozic","year":"2017","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Pinto, B., Novais, P., Henriques, A.C., Carvalho-Tavares, J., Silva, P.M.A., and Bousbaa, H. (2022). Navitoclax Enhances the Therapeutic Effects of PLK1 Targeting on Lung Cancer Cells in 2D and 3D Culture Systems. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061209"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3322\/caac.21389","article-title":"Head and Neck Cancers-Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual","volume":"67","author":"Lydiatt","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11912-019-0799-x","article-title":"Changes in the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging of Head and Neck Cancer: Rationale and Implications","volume":"21","author":"Zanoni","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s12250-021-00413-8","article-title":"Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care","volume":"36","author":"Dong","year":"2021","journal-title":"Virol. Sin."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cden.2017.08.006","article-title":"Chemotherapy for Oral Cancer","volume":"62","author":"Hartner","year":"2018","journal-title":"Dent. Clin. N. Am."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.canlet.2018.10.005","article-title":"Mitosis Inhibitors in Anticancer Therapy: When Blocking the Exit Becomes a Solution","volume":"440\u2013441","author":"Henriques","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Anand, U., Dey, A., Chandel, A.K.S., Sanyal, R., Mishra, A., Pandey, D.K., De Falco, V., Upadhyay, A., Kandimalla, R., and Chaudhary, A. (2022). Cancer Chemotherapy and beyond: Current Status, Drug Candidates, Associated Risks and Progress in Targeted Therapeutics. Genes Dis.","DOI":"10.1016\/j.gendis.2022.02.007"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3389\/fonc.2019.00383","article-title":"Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","volume":"9","author":"Taberna","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(21)00076-0","article-title":"Chemotherapy and Radiotherapy in Locally Advanced Head and Neck Cancer: An Individual Patient Data Network Meta-Analysis","volume":"22","author":"Petit","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fonc.2017.00072","article-title":"Evidence-Based Treatment Options in Recurrent and\/or Metastatic Squamous Cell Carcinoma of the Head and Neck","volume":"7","author":"Argiris","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/S0140-6736(21)01550-6","article-title":"Head and Neck Cancer","volume":"398","author":"Mody","year":"2021","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab Alone or with Chemotherapy versus Cetuximab with Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-048): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fonc.2019.00388","article-title":"Current Role of Surgery in the Management of Oropharyngeal Cancer","volume":"9","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ribeiro-Rotta, R.F., Rosa, E.A., Milani, V., Dias, N.R., Masterson, D., da Silva, E.N., and de Sene Am\u00e2ncio Zara, A.L. (2022). The Cost of Oral Cancer: A Systematic Review. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0266346"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2478\/raon-2021-0041","article-title":"Definitive Radiotherapy for Squamous Cell Carcinoma of the Oral Cavity: A Single-Institution Experience","volume":"55","author":"Lang","year":"2021","journal-title":"Radiol. Oncol."},{"key":"ref_32","unstructured":"Dhawan, A. (2021). Oral and Maxillofacial Surgery for the Clinician, Springer Nature."},{"key":"ref_33","first-page":"e15","article-title":"Protocols for Management of Oral Complications of Chemotherapy and\/or Radiotherapy for Oral Cancer: Systematic Review and Meta-Analysis Current","volume":"22","author":"Moura","year":"2016","journal-title":"Med. Oral Patol. Oral Y Cir. Bucal."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2015.2","article-title":"DNA Damage and the Balance between Survival and Death in Cancer Biology","volume":"16","author":"Roos","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA Damage Repair: Historical Perspectives, Mechanistic Pathways and Clinical Translation for Targeted Cancer Therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.3390\/biom5043204","article-title":"DNA Damage Signalling and Repair Inhibitors: The Long-Sought-after Achilles\u2019 Heel of Cancer","volume":"5","author":"Velic","year":"2015","journal-title":"Biomolecules"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.18632\/aging.202297","article-title":"Antitumor Effect of Poly Lactic Acid Nanoparticles Loaded with Cisplatin and Chloroquine on the Oral Squamous Cell Carcinoma","volume":"13","author":"Li","year":"2021","journal-title":"Aging"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"112328","DOI":"10.1016\/j.biopha.2021.112328","article-title":"The Role of Natural Antioxidants in Cisplatin-Induced Hepatotoxicity","volume":"144","author":"Teoh","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"761379","DOI":"10.3389\/fonc.2021.761379","article-title":"The Molecular Basis and Therapeutic Aspects of Cisplatin Resistance in Oral Squamous Cell Carcinoma","volume":"11","author":"Cheng","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_40","unstructured":"Riddell, I.A., and Lippard, S.J. (2018). Metallo-Drugs: Development and Action of Anticancer Agents Actions, De Gruyter."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-Fluorouracil: Mechanisms of Action and Clinical Strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Pozzi, C., Lopresti, L., Tassone, G., and Mangani, S. (2019). Targeting Methyltransferases in Human Pathogenic Bacteria: Insights into Thymidylate Synthase (TS) and Flavin-Dependent TS (FDTS). Molecules, 24.","DOI":"10.3390\/molecules24081638"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12029-017-9946-5","article-title":"The Role of Fluoropirimidines in Gastrointestinal Tumours: From the Bench to the Bed","volume":"48","author":"Capdevila","year":"2017","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1208\/s12249-022-02221-z","article-title":"Transfersome Hydrogel Containing 5-Fluorouracil and Etodolac Combination for Synergistic Oral Cancer Treatment","volume":"23","author":"Bollareddy","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High Sensitivity of BRCA1-Deficient Mammary Tumors to the PARP Inhibitor AZD2281 Alone and in Combination with Platinum Drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"102651","DOI":"10.1016\/j.dnarep.2019.102651","article-title":"PARP-1 and Its Associated Nucleases in DNA Damage Response","volume":"81","author":"Wang","year":"2019","journal-title":"DNA Repair (Amst)."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Yasukawa, M., Fujihara, H., Fujimori, H., Kawaguchi, K., Yamada, H., Nakayama, R., Yamamoto, N., Kishi, Y., Hamada, Y., and Masutani, M. (2016). Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17030272"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"105171","DOI":"10.1016\/j.oraloncology.2020.105171","article-title":"A Phase I Trial Adding Poly(ADP-Ribose) Polymerase Inhibitor Veliparib to Induction Carboplatin-Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Alliance A091101","volume":"114","author":"Jelinek","year":"2021","journal-title":"Oral Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3389\/fphar.2019.00557","article-title":"Natural Product Target Network Reveals Potential for Cancer Combination Therapies","volume":"10","author":"Chamberlin","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"103157","DOI":"10.1016\/j.dnarep.2021.103157","article-title":"Olaparib Enhances Curcumin-Mediated Apoptosis in Oral Cancer Cells by Inducing PARP Trapping through Modulation of BER and Chromatin Assembly","volume":"105","author":"Molla","year":"2021","journal-title":"DNA Repair"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"109902","DOI":"10.1016\/j.cellsig.2020.109902","article-title":"PARP Inhibitor Veliparib (ABT-888) Enhances the Anti-Angiogenic Potentiality of Curcumin through Deregulation of NECTIN-4 in Oral Cancer: Role of Nitric Oxide (NO)","volume":"80","author":"Chatterjee","year":"2021","journal-title":"Cell. Signal."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1007\/s00432-022-04269-7","article-title":"Combination of Talazoparib and Olaparib Enhanced the Curcumin-Mediated Apoptosis in Oral Cancer Cells by PARP-1 Trapping","volume":"148","author":"Chatterjee","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_53","first-page":"379","article-title":"Combination Treatment with Arsenic Trioxide and Sulindac Enhances Apoptotic Cell Death in Lung Cancer Cells via Activation of Oxidative Stress and Mitogen-Activated Protein Kinases","volume":"20","author":"Kim","year":"2008","journal-title":"Oncol. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1349-7006.2006.00230.x","article-title":"Opposing Effects of Arsenic Trioxide on Hepatocellular Carcinomas in Mice","volume":"97","author":"Liu","year":"2006","journal-title":"Cancer Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","article-title":"Acute Promyelocytic Leukemia: From Highly Fatal to Highly Curable","volume":"111","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s13402-014-0167-7","article-title":"Combined Arsenic Trioxide-Cisplatin Treatment Enhances Apoptosis in Oral Squamous Cell Carcinoma Cells","volume":"37","author":"Nakaoka","year":"2014","journal-title":"Cell. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3389\/fonc.2020.00463","article-title":"Combinatorial Low Dose Arsenic Trioxide and Cisplatin Exacerbates Autophagy via AMPK\/STAT3 Signaling on Targeting Head and Neck Cancer Initiating Cells","volume":"10","author":"Hu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Wang, S.-C., Chang, M.-Y., Shiau, J.-P., Farooqi, A.A., Huang, Y.-H., Tang, J.-Y., and Chang, H.-W. (2022). Antiproliferation- and Apoptosis-Inducible Effects of a Novel Nitrated [6,6,6]Tricycle Derivative (SK2) on Oral Cancer Cells. Molecules, 27.","DOI":"10.3390\/molecules27051576"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Wang, S.-C., Yen, C.-Y., Shiau, J.-P., Chang, M.-Y., Hou, M.-F., Jeng, J.-H., Tang, J.-Y., and Chang, H.-W. (2022). Synergistic Antiproliferation of Cisplatin and Nitrated [6,6,6]Tricycle Derivative (SK2) for a Combined Treatment of Oral Cancer Cells. Antioxidants, 11.","DOI":"10.3390\/antiox11050926"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.tiv.2015.07.008","article-title":"Dissociation of E-Cadherin\/\u03b2-Catenin Complex by MG132 and Bortezomib Enhances CDDP Induced Cell Death in Oral Cancer SCC-25 Cells","volume":"29","author":"Liu","year":"2015","journal-title":"Toxicol. Vitr."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3892\/etm.2023.11924","article-title":"Proteasome Inhibitor MG132 Enhances the Sensitivity of Human OSCC Cells to Cisplatin via a ROS\/DNA Damage\/P53 Axis","volume":"25","author":"Zheng","year":"2023","journal-title":"Exp. Ther. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00066-011-0043-6","article-title":"The Combination of Hyperthermia or Chemotherapy with Gimeracil for Effective Radiosensitization","volume":"188","author":"Takagi","year":"2012","journal-title":"Strahlenther. Und Onkol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.21873\/anticanres.11179","article-title":"Gimeracil Exerts Radiosensitizing Effects on Oral Squamous Cell Carcinoma Cells in Vitro and in Vivo","volume":"36","author":"Harada","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.3892\/ol.2017.6602","article-title":"Gimeracil Enhances the Antitumor Effect of Cisplatin in Oral Squamous Cell Carcinoma Cells in Vitro and in Vivo","volume":"14","author":"Harada","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"BSR20202083","DOI":"10.1042\/BSR20202083","article-title":"Suppression of Oral Cancer by Induction of Cell Cycle Arrest and Apoptosis Using Juniperus Communis Extract","volume":"40","author":"Lee","year":"2020","journal-title":"Biosci. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3349\/ymj.2011.52.5.773","article-title":"The Bacterial Protein AAzurin Enhances Sensitivity of Oral Squamous Carcinoma Cells to Anticancer Drugs","volume":"52","author":"Choi","year":"2011","journal-title":"Yonsei Med. J."},{"key":"ref_67","first-page":"649","article-title":"FASN Inhibition Sensitizes Metastatic OSCC Cells to Cisplatin and Paclitaxel by Downregulating Cyclin B1","volume":"29","author":"Ortiz","year":"2021","journal-title":"Oral Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.2147\/CMAR.S312989","article-title":"Propofol Suppresses Gastric Cancer Progression by Regulating Circpdss1\/Mir-1324\/Sox4 Axis","volume":"13","author":"Liu","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_69","first-page":"402","article-title":"Propofol Inhibits Wnt Signaling and Exerts Anticancer Activity in Glioma Cells","volume":"16","author":"Xu","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3892\/mmr.2021.12552","article-title":"Propofol Induces Apoptosis and Ameliorates 5-fluorouracil Resistance in OSCC Cells by Reducing the Expression and Secretion of Amphiregulin","volume":"25","author":"Yang","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/bs.podrm.2017.02.006","article-title":"Propranolol","volume":"Volume 42","author":"Bakheit","year":"2017","journal-title":"Profiles of Drug Substances, Excipients and Related Methodology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.biopha.2018.05.002","article-title":"Anti-Tumor Effects of Propranolol: Adjuvant Activity on a Transplanted Murine Breast Cancer Model","volume":"104","author":"Ashrafi","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"105383","DOI":"10.1016\/j.archoralbio.2022.105383","article-title":"Propranolol Inhibits Cell Viability and Expression of the Pro-Tumorigenic Proteins Akt, NF-\u0138B, and VEGF in Oral Squamous Cell Carcinoma","volume":"136","author":"Shibuya","year":"2022","journal-title":"Arch. Oral Biol."},{"key":"ref_74","first-page":"2527","article-title":"Changes of Serum MiR-223-3p in Patients with Oral Cancer Treated with TPF Regimen and the Prognosis","volume":"19","author":"Li","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/cas.14323","article-title":"Stathmin Guides Personalized Therapy in Oral Squamous Cell Carcinoma","volume":"111","author":"Ju","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/cncr.32539","article-title":"Phase 1 Dose-Finding Study of Metformin in Combination with Concurrent Cisplatin and Radiotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Cancer","volume":"126","author":"Gulati","year":"2020","journal-title":"Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"104753","DOI":"10.1016\/j.oraloncology.2020.104753","article-title":"Phase I Trial of Alpelisib in Combination with Concurrent Cisplatin-Based Chemoradiotherapy in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck","volume":"108","author":"Day","year":"2020","journal-title":"Oral Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/1097-0142(20010801)92:3<556::AID-CNCR1355>3.0.CO;2-Q","article-title":"Expression of Vascular Endothelial Growth Factor Family Members in Head and Neck Squamous Cell Carcinoma Correlates with Lymph Node Metastasis","volume":"92","author":"Eccles","year":"2001","journal-title":"Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2000.18.10.2046","article-title":"Prognostic Significance of Vascular Endothelial Growth Factor Protein Levels in Oral and Oropharyngeal Squamous Cell Carcinoma","volume":"18","author":"Smith","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1001-9294(17)30004-4","article-title":"Clinical Observation of Bevacizumab Combined with S-1 in the Treatment of Pretreated Advanced Esophageal Carcinoma","volume":"31","author":"Nie","year":"2016","journal-title":"Chin. Med. Sci. J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000446372","article-title":"A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study)","volume":"91","author":"Yoshida","year":"2016","journal-title":"Oncology"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Tsukahara, K., Kubota, A., Hasegawa, Y., Takemura, H., Terada, T., Taguchi, T., Nagahara, K., Nakatani, H., Yoshino, K., and Higaki, Y. (2015). Randomized Phase III Trial of Adjuvant Chemotherapy with S-1 after Curative Treatment in Patients with Squamous-Cell Carcinoma of the Head and Neck (ACTS-HNC). PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0116965"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3892\/ol.2021.12991","article-title":"Antitumor Effects of Bevacizumab in Combination with Fluoropyrimidine Drugs on Human Oral Squamous Cell Carcinoma","volume":"22","author":"Itashiki","year":"2021","journal-title":"Oncol. Lett."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1158\/1078-0432.CCR-20-1727","article-title":"Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma","volume":"26","author":"Chong","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"25849","DOI":"10.18632\/oncotarget.8405","article-title":"TRPV4 Channels Regulate Tumor Angiogenesis via Modulation of Rho\/Rho Kinase Pathway","volume":"7","author":"Thoppil","year":"2016","journal-title":"Oncotarget"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Yahya, F., Mohd Bakri, M., Hossain, M., Syed Abdul Rahman, S., Mohammed Alabsi, A., and Ramanathan, A. (2022). Combination Treatment of TRPV4 Agonist with Cisplatin Promotes Vessel Normalization in an Animal Model of Oral Squamous Cell Carcinoma. Medicina, 58.","DOI":"10.3390\/medicina58091229"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/jnc.14957","article-title":"Angiopoietin-1\/Tie-2 Signal after Focal Traumatic Brain Injury Is Potentiated by BQ788, an ET B Receptor Antagonist, in the Mouse Cerebrum: Involvement in Recovery of Blood\u2013Brain Barrier Function","volume":"154","author":"Michinaga","year":"2020","journal-title":"J. Neurochem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ccr.2014.04.026","article-title":"B Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas","volume":"25","author":"Affara","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Hsieh, C.-Y., Lien, M.-Y., Lin, C.-Y., Lo, W.-J., Hua, C.-H., Chang, W.-C., Chiu, C.-F., and Lin, C.-C. (2022). Rituximab in Combination with Gemcitabine plus Cisplatin in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I Trial. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09258-0"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S1470-2045(20)30327-2","article-title":"Debio 1143 and High-Dose Cisplatin Chemoradiotherapy in High-Risk Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Double-Blind, Multicentre, Randomised, Phase 2 Study","volume":"21","author":"Sun","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2022.12.015","article-title":"Extended Follow-up of a Phase 2 Trial of Xevinapant plus Chemoradiotherapy in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomised Clinical Trial","volume":"183","author":"Tao","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s10637-022-01235-5","article-title":"Phase II Study of Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase, in Combination with Chemoradiotherapy for Unresected, Locally Advanced Head and Neck Squamous Cell Carcinoma","volume":"40","author":"Powell","year":"2022","journal-title":"Investig. New Drugs"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.12998\/wjcc.v10.i11.3414","article-title":"Concurrent Chemoradiotherapy Using Gemcitabine and Nedaplatin in Recurrent or Locally Advanced Head and Neck Squamous Cell Carcinoma","volume":"10","author":"Huo","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/CAD.0000000000000222","article-title":"Optimized Combinations of Bortezomib, Camptothecin, and Doxorubicin Show Increased Efficacy and Reduced Toxicity in Treating Oral Cancer","volume":"26","author":"Ding","year":"2015","journal-title":"Anticancer Drugs"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.21.01293","article-title":"Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II\/III Randomized Controlled Trial","volume":"40","author":"Kiyota","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/annonc\/mdx202","article-title":"A Two-Arm Multicenter Phase II Trial of One Cycle Chemoselection Split-Dose Docetaxel, Cisplatin and 5-Fluorouracil (TPF) Induction Chemotherapy before Two Cycles of Split TPF Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patien","volume":"28","author":"Inhestern","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cac2.12136","article-title":"Phase III Trial of Docetaxel Cisplatin 5-Fluorouracil Induction Chemotherapy for Resectable Oral Cancer Suggests Favorable Pathological Response as a Surrogate Endpoint for Good Therapeutic Outcome","volume":"41","author":"Ju","year":"2021","journal-title":"Cancer Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1002\/cam4.5075","article-title":"Assessment of Neoadjuvant Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil in Patients with Oral Cavity Cancer","volume":"12","author":"Fu","year":"2023","journal-title":"Cancer Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/path.1642","article-title":"Frequent Overexpression of Multiple ErbB Receptors by Head and Neck Squamous Cell Carcinoma Contrasts with Rare Antibody Immunity in Patients","volume":"204","author":"Bei","year":"2004","journal-title":"J. Pathol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1309\/BTLN5WTMJ3PCNRRC","article-title":"Expression of Protein Tyrosine Kinases in Head and Neck Squamous Cell Carcinomas","volume":"124","author":"Ongkeko","year":"2005","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_101","first-page":"817304","article-title":"Advances in Targeting HER3 as an Anticancer Therapy","volume":"2012","author":"Jiang","year":"2012","journal-title":"Chemother. Res. Pract."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1038\/onc.2016.393","article-title":"Extracellular Region of Epidermal Growth Factor Receptor: A Potential Target for Anti-EGFR Drug Discovery","volume":"36","author":"Dokala","year":"2017","journal-title":"Oncogene"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00018-008-7440-8","article-title":"The Epidermal Growth Factor Receptor Family: Biology Driving Targeted Therapeutics","volume":"65","author":"Wieduwilt","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Wee, P., and Wang, Z. (2017). Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers, 9.","DOI":"10.3390\/cancers9050052"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging Functions of the EGFR in Cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-16-0558","article-title":"HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2\/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"678966","DOI":"10.3389\/fonc.2021.678966","article-title":"EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers","volume":"11","author":"Mock","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_108","first-page":"189","article-title":"Mechanisms Underlying Resistance to Cetuximab in the HNSCC Cell Line: Role of AKT Inhibition in Bypassing This Resistance","volume":"38","author":"Rebucci","year":"2010","journal-title":"Int. J. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3389\/fonc.2019.00800","article-title":"Rethink of EGFR in Cancer With Its Kinase Independent Function on Board","volume":"9","author":"Thomas","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2015.213","article-title":"Kinase Inhibitors and Monoclonal Antibodies in Oncology: Clinical Implications","volume":"13","author":"Gharwan","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Golay, J., and Taylor, R.P. (2020). The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer MAbs. Antibodies, 9.","DOI":"10.3390\/antib9040058"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/era.12.91","article-title":"Current Role of EGF Receptor Monoclonal Antibodies and Tyrosine Kinase Inhibitors in the Management of Head and Neck Squamous Cell Carcinoma","volume":"12","author":"Markovic","year":"2012","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.critrevonc.2006.12.008","article-title":"EGFR Targeting Therapies: Monoclonal Antibodies versus Tyrosine Kinase Inhibitors","volume":"62","author":"Dassonville","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12967-015-0531-z","article-title":"Epidermal Growth Factor Receptor Immunohistochemistry: New Opportunities in Metastatic Colorectal Cancer","volume":"13","author":"Hutchinson","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/hed.26635","article-title":"Phase II Study of Nimotuzumab (TheraCim-HR3) Concurrent with Cisplatin\/Radiotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma","volume":"43","author":"Ang","year":"2021","journal-title":"Head Neck"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1158\/1078-0432.CCR-21-0426","article-title":"Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer","volume":"28","author":"Ferris","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"635096","DOI":"10.3389\/fonc.2021.635096","article-title":"Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab","volume":"11","author":"Pogorzelski","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2326-6066.CIR-16-0333","article-title":"Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients","volume":"5","author":"Jie","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Fenoglio, D., Belgioia, L., Parodi, A., Missale, F., Bacigalupo, A., Tarke, A., Incandela, F., Negrini, S., Vecchio, S., and Altosole, T. (2021). Development of Exhaustion and Acquisition of Regulatory Function by Infiltrating CD8+CD28\u2212 T Lymphocytes Dictate Clinical Outcome in Head and Neck Cancer. Cancers, 13.","DOI":"10.3390\/cancers13092234"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hed.24560","article-title":"Combination of Phosphotidylinositol-3-Kinase Targeting with Cetuximab and Irradiation: A Preclinical Study on an Orthotopic Xenograft Model of Head and Neck Cancer","volume":"39","author":"Bozec","year":"2017","journal-title":"Head Neck"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Otsuru, M., Yanamoto, S., Yamada, S., Nakashiro, K., Harazono, Y., Kohgo, T., Nakamura, M., Nomura, T., Kasamatsu, A., and Tanaka, S. (2023). Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20054545"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hed.23837","article-title":"Radioresistance in Head and Neck Squamous Cell Carcinoma: Biological Bases and Therapeutic Implications","volume":"37","author":"Perri","year":"2015","journal-title":"Head Neck"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1517\/14728222.2015.1012157","article-title":"Targeting EGFR-PI3K-AKT-MTOR Signaling Enhances Radiosensitivity in Head and Neck Squamous Cell Carcinoma","volume":"19","author":"Horn","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1158\/1078-0432.CCR-15-2245","article-title":"Taselisib (GDC-0032), a Potent \u03b2-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations","volume":"22","author":"Zumsteg","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_126","first-page":"885","article-title":"Local Recurrence in Head and Neck Cancer: Relationship to Radiation Resistance and Signal Transduction","volume":"8","author":"Gupta","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1158\/1078-0432.CCR-14-3279","article-title":"Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K\/MTOR Inhibitor PF-05212384","volume":"21","author":"Leiker","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/annonc\/mdu574","article-title":"A Randomized, Phase II Trial of Cetuximab with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Head and Neck Squamous Cell Cancer","volume":"26","author":"Jimeno","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s10637-021-01152-z","article-title":"Phase I Trial of Copanlisib, a Selective PI3K Inhibitor, in Combination with Cetuximab in Patients with Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinoma","volume":"39","author":"Marret","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.07.011","article-title":"A Phase 1b Study of Afatinib in Combination with Standard-Dose Cetuximab in Patients with Advanced Solid Tumours","volume":"104","author":"Gazzah","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ijrobp.2019.09.050","article-title":"A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma","volume":"106","author":"Dunn","year":"2020","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1158\/0008-5472.CAN-18-0459","article-title":"BET Inhibition Overcomes Receptor Tyrosine Kinase\u2013Mediated Cetuximab Resistance in HNSCC","volume":"78","author":"Leonard","year":"2018","journal-title":"Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.celrep.2015.03.037","article-title":"Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains","volume":"11","author":"Stuhlmiller","year":"2015","journal-title":"Cell Rep."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ccell.2015.05.006","article-title":"Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy","volume":"27","author":"Stratikopoulos","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1667\/RR15480.1","article-title":"Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models","volume":"194","author":"Frederick","year":"2020","journal-title":"Radiat. Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"607428","DOI":"10.3389\/fgene.2020.607428","article-title":"DNA-PKcs: A Multi-Faceted Player in DNA Damage Response","volume":"11","author":"Yue","year":"2020","journal-title":"Front. Genet."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Nowsheen, S., Bonner, J.A., LoBuglio, A.F., Trummell, H., Whitley, A.C., Dobelbower, M.C., and Yang, E.S. (2011). Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck Cancer. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024148"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"599","DOI":"10.18632\/oncotarget.311","article-title":"Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck","volume":"2","author":"Hoellein","year":"2011","journal-title":"Oncotarget"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.oraloncology.2012.06.016","article-title":"Overcoming Resistance to EGFR Inhibitor in Head and Neck Cancer: A Review of the Literature","volume":"48","author":"Rabinowits","year":"2012","journal-title":"Oral Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fcell.2015.00050","article-title":"Functions of Aurora Kinase C in Meiosis and Cancer","volume":"3","author":"Quartuccio","year":"2015","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/j.1582-4934.2009.00919.x","article-title":"Translational Up-Regulation of Aurora-A in EGFR-Overexpressed Cancer","volume":"14","author":"Lai","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1128\/MCB.01286-14","article-title":"Aurora B Overexpression Causes Aneuploidy and P21 Cip1 Repression during Tumor Development","volume":"35","author":"Trakala","year":"2015","journal-title":"Mol. Cell. Biol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1080\/15384101.2019.1643658","article-title":"Identification and Evaluation of Novel Drug Combinations of Aurora Kinase Inhibitor CCT137690 for Enhanced Efficacy in Oral Cancer Cells","volume":"18","author":"Furqan","year":"2019","journal-title":"Cell Cycle"},{"key":"ref_144","first-page":"6323","article-title":"Synergistic Inhibitory Effects of Cetuximab and Curcumin on Human Cisplatin-Resistant Oral Cancer CAR Cells through Intrinsic Apoptotic Process","volume":"16","author":"Chen","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Jozkowiak, M., Dyszkiewicz-Konwinska, M., Ramlau, P., Kranc, W., Spaczynska, J., Wierzchowski, M., Kaczmarek, M., Jodynis-Liebert, J., and Piotrowska-Kempisty, H. (2021). Individual and Combined Treatments with Methylated Resveratrol Analogue Dmu-214 and Gefitinib Inhibit Tongue Cancer Cells Growth via Apoptosis Induction and Egfr Inhibition. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126180"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/cncr.29224","article-title":"A Phase 1 Study of Cetuximab and Lapatinib in Patients with Advanced Solid Tumor Malignancies","volume":"121","author":"Deeken","year":"2015","journal-title":"Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2019.08.017","article-title":"Patritumab or Placebo, with Cetuximab plus Platinum Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Randomised Phase II Study","volume":"123","author":"Forster","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11523-019-00626-8","article-title":"Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models","volume":"14","author":"Yee","year":"2019","journal-title":"Target. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1024-e89","DOI":"10.1634\/theoncologist.2017-0175","article-title":"A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS","volume":"22","author":"Lieu","year":"2017","journal-title":"Oncologist"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12967-015-0633-7","article-title":"Activation of MET Pathway Predicts Poor Outcome to Cetuximab in Patients with Recurrent or Metastatic Head and Neck Cancer","volume":"13","author":"Zazo","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Rothenberger, N.J., and Stabile, L.P. (2017). Hepatocyte Growth Factor\/c-Met Signaling in Head and Neck Cancer and Implications for Treatment. Cancers, 9.","DOI":"10.3390\/cancers9040039"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/cncr.32762","article-title":"A Randomized Phase 2 Network Trial of Tivantinib plus Cetuximab versus Cetuximab in Patients with Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma","volume":"126","author":"Kochanny","year":"2020","journal-title":"Cancer"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.oraloncology.2014.12.011","article-title":"A Randomized Phase II Efficacy and Correlative Studies of Cetuximab with or without Sorafenib in Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinoma","volume":"51","author":"Gilbert","year":"2015","journal-title":"Oral Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ijrobp.2003.09.091","article-title":"Acquired Resistance to EGFR Inhibitors: Mechanisms and Prevention Strategies","volume":"58","author":"Kerbel","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/annonc\/mds245","article-title":"Cetuximab and Bevacizumab: Preclinical Data and Phase II Trial in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","volume":"24","author":"Argiris","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","article-title":"Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab as a Single Agent in Patients with Recurrent and\/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based The","volume":"25","author":"Vermorken","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/jco.2010.28.15_suppl.5501","article-title":"BIBW 2992 versus Cetuximab in Patients with Metastatic or Recurrent Head and Neck Cancer (SCCHN) after Failure of Platinum-Containing Therapy with a Cross-over Period for Progressing Patients: Preliminary Results of a Randomized, Open-Label Phase II Study","volume":"28","author":"Seiwert","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S1470-2045(18)30350-4","article-title":"Pazopanib plus Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-Label, Phase 1b and Expansion Study","volume":"19","author":"Adkins","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jpedsurg.2012.10.016","article-title":"HIF-1\u03b1 Activation Mediates Resistance to Anti-Angiogenic Therapy in Neuroblastoma Xenografts","volume":"48","author":"Hartwich","year":"2013","journal-title":"J. Pediatr. Surg."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1053\/j.seminoncol.2009.10.013","article-title":"Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma","volume":"36","author":"Hudes","year":"2009","journal-title":"Semin. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"23227","DOI":"10.18632\/oncotarget.7594","article-title":"Advanced Malignancies Treated with a Combination of the VEGF Inhibitor Bevacizumab, Anti-EGFR Antibody Cetuximab, and the MTOR Inhibitor Temsirolimus","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/cncr.32929","article-title":"A Randomized Phase 2 Study of Temsirolimus and Cetuximab versus Temsirolimus Alone in Recurrent\/Metastatic, Cetuximab-resistant Head and Neck Cancer: The MAESTRO Study","volume":"126","author":"Seiwert","year":"2020","journal-title":"Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/annonc\/mdv194","article-title":"Phase II Trial of Everolimus and Erlotinib in Patients with Platinum-Resistant Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinoma","volume":"26","author":"Massarelli","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.19.00555","article-title":"Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer","volume":"37","author":"Argiris","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1002\/cncr.27498","article-title":"A Phase 2 Study of Bevacizumab with Cisplatin plus Intensity-Modulated Radiation Therapy for Stage III\/IVB Head and Neck Squamous Cell Cancer","volume":"118","author":"Fury","year":"2012","journal-title":"Cancer"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"E566","DOI":"10.1002\/hed.24041","article-title":"Phase II Trial of Bevacizumab + Cetuximab + Cisplatin with Concurrent Intensity-Modulated Radiation Therapy for Patients with Stage III\/IVB Head and Neck Squamous Cell Carcinoma","volume":"38","author":"Fury","year":"2016","journal-title":"Head Neck"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Nozaki, M., Yasui, H., and Ohnishi, Y. (2019). Ligand-Independent EGFR Activation by Anchorage-Stimulated Src Promotes Cancer Cell Proliferation and Cetuximab Resistance via ErbB3 Phosphorylation. Cancers, 11.","DOI":"10.20944\/preprints201909.0037.v1"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1158\/1535-7163.MCT-17-0351","article-title":"T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non\u2013Small Cell Lung Cancer","volume":"16","author":"Watanabe","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1158\/1541-7786.MCR-19-0741","article-title":"Combined Src\/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer","volume":"18","author":"Dosch","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e90449","DOI":"10.1172\/jci.insight.90449","article-title":"Randomized, Placebo-Controlled Window Trial of EGFR, Src, or Combined Blockade in Head and Neck Cancer","volume":"2","author":"Bauman","year":"2017","journal-title":"JCI Insight"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.oraloncology.2017.03.011","article-title":"IL6 Is Associated with Response to Dasatinib and Cetuximab: Phase II Clinical Trial with Mechanistic Correlatives in Cetuximab-Resistant Head and Neck Cancer","volume":"69","author":"Stabile","year":"2017","journal-title":"Oral Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12032-021-01557-z","article-title":"Combinatorial Treatment with Gefitinib and Bay11-7085 Sensitizes Primary Gefitinib-Resistant OSCC Cells by Influencing the EGFR- NF\u03baB Signaling Axis","volume":"38","author":"Sinto","year":"2021","journal-title":"Med. Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13045-020-00904-3","article-title":"Insulin-like Growth Factor Receptor Signaling in Tumorigenesis and Drug Resistance: A Challenge for Cancer Therapy","volume":"13","author":"Hua","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1158\/1535-7163.MCT-11-0294","article-title":"Activation of the Insulin-like Growth Factor-1 Receptor Induces Resistance to Epidermal Growth Factor Receptor Antagonism in Head and Neck Squamous Carcinoma Cells","volume":"10","author":"Jameson","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.oraloncology.2018.05.014","article-title":"Randomized Phase II Trial of Cixutumumab Alone or with Cetuximab for Refractory Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma","volume":"82","author":"Ferrarotto","year":"2018","journal-title":"Oral Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Sawatani, Y., Komiyama, Y., Nakashiro, K.I., Uchida, D., Fukumoto, C., Shimura, M., Hasegawa, T., Kamimura, R., Hitomi-Koide, M., and Hyodo, T. (2020). Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells in Vitro. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176292"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2015.02.014","article-title":"The Relevance of ADCC for EGFR Targeting: A Review of the Literature and a Clinically-Applicable Method of Assessment in Patients","volume":"95","author":"Monteverde","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","article-title":"NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy","volume":"6","author":"Wang","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"105546","DOI":"10.1016\/j.oraloncology.2021.105546","article-title":"Tipifarnib Enhances Anti-EGFR Activity of Cetuximab in Non-HRas Mutated Head and Neck Squamous Cell Carcinoma Cancer (HNSCC)","volume":"122","author":"Shu","year":"2021","journal-title":"Oral Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"638","DOI":"10.2174\/138955709788452702","article-title":"Farnesyltransferase Inhibitor as Anticancer Agent","volume":"9","author":"Agrawal","year":"2009","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","article-title":"K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors","volume":"272","author":"Whyte","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1634\/theoncologist.2007-0204","article-title":"Clinical Efficacy of Taxane\u2013Trastuzumab Combination Regimens for HER-2\u2013Positive Metastatic Breast Cancer","volume":"13","author":"Bullock","year":"2008","journal-title":"Oncologist"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/17843286.2016.1173940","article-title":"Metastatic HER-2-Positive Salivary Gland Carcinoma Treated with Trastuzumab and a Taxane: A Series of Six Patients","volume":"71","author":"Dormaar","year":"2016","journal-title":"Acta Clin. Belgica Int. J. Clin. Lab. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II Trial of Trastuzumab and Docetaxel in Patients with Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijrobp.2019.04.034","article-title":"A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck","volume":"105","author":"Margalit","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.oraloncology.2016.09.009","article-title":"Phase II Study of Panitumumab and Paclitaxel as First-Line Treatment in Recurrent or Metastatic Head and Neck Cancer. TTCC-2009-03\/VECTITAX Study","volume":"62","author":"Berrocal","year":"2016","journal-title":"Oral Oncol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1007\/s12094-021-02567-z","article-title":"Sequential Chemotherapy Regimen of Induction with Panitumumab and Paclitaxel Followed by Radiotherapy and Panitumumab in Patients with Locally Advanced Head and Neck Cancer Unfit for Platinum Derivatives. The Phase II, PANTERA\/TTCC-2010-06 Study","volume":"23","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hed.24766","article-title":"Effectiveness of Incorporating Cetuximab into Docetaxel\/Cisplatin\/Fluorouracil Induction Chemotherapy and Chemoradiotherapy for Inoperable Squamous Cell Carcinoma of the Oral Cavity: A Phase II Study","volume":"39","author":"Chang","year":"2017","journal-title":"Head Neck"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.oraloncology.2017.07.001","article-title":"Nab-Paclitaxel-Based Induction Chemotherapy with or without Cetuximab for Locally Advanced Head and Neck Squamous Cell Carcinoma","volume":"72","author":"Adkins","year":"2017","journal-title":"Oral Oncol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/annonc\/mdr367","article-title":"Phase II Study of the Combination of Cetuximab and Weekly Paclitaxel in the First-Line Treatment of Patients with Recurrent and\/or Metastatic Squamous Cell Carcinoma of Head and Neck","volume":"23","author":"Hitt","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/annonc\/mdy040","article-title":"Phase II Trial of Combination Treatment with Paclitaxel, Carboplatin and Cetuximab (PCE) as First-Line Treatment in Patients with Recurrent and\/or Metastatic Squamous Cell Carcinoma of the Head and Neck (CSPOR-HN02)","volume":"29","author":"Tahara","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/cam4.2852","article-title":"A Multicenter Phase II Trial of Paclitaxel, Carboplatin, and Cetuximab Followed by Chemoradiotherapy in Patients with Unresectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck","volume":"9","author":"Enokida","year":"2020","journal-title":"Cancer Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"526-e49","DOI":"10.1634\/theoncologist.2017-0661","article-title":"Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinomas","volume":"23","author":"William","year":"2018","journal-title":"Oncologist"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1093\/annonc\/mdx439","article-title":"A Randomized, Phase 2 Study of Cetuximab plus Cisplatin with or without Paclitaxel for the First-Line Treatment of Patients with Recurrent and\/or Metastatic Squamous Cell Carcinoma of the Head and Neck","volume":"28","author":"Bossi","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1073274821997444","DOI":"10.1177\/1073274821997444","article-title":"Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial","volume":"28","author":"Zheng","year":"2021","journal-title":"Cancer Control"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40268-017-0204-x","article-title":"The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro","volume":"17","author":"Khalil","year":"2017","journal-title":"Drugs R D"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(20)30755-5","article-title":"Cetuximab, Docetaxel, and Cisplatin versus Platinum, Fluorouracil, and Cetuximab as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (GORTEC 2014-01 TPExtreme): A Multicentre, Open-Label, Randomised, Phas","volume":"22","author":"Guigay","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hed.26053","article-title":"Methotrexate plus or Minus Cetuximab as First-Line Treatment in a Recurrent or Metastatic (R\/M) Squamous Cell Carcinoma Population of the Head and Neck (SCCHN), Unfit for Cisplatin Combination Treatment, a Phase Ib-Randomized Phase II Study Commence","volume":"42","author":"Ham","year":"2020","journal-title":"Head Neck"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/coa.13316","article-title":"Cetuximab and Methotrexate in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma\u2014A Single Institution Analysis of 54 Patients","volume":"44","author":"Sukari","year":"2019","journal-title":"Clin. Otolaryngol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10637-016-0367-2","article-title":"Phase I Trial of Dacomitinib, a Pan-Human Epidermal Growth Factor Receptor (HER) Inhibitor, with Concurrent Radiotherapy and Cisplatin in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (XDC-001)","volume":"34","author":"Prawira","year":"2016","journal-title":"Investig. New Drugs"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hed.23922","article-title":"Phase I Study of Vandetanib with Radiation Therapy with or without Cisplatin in Locally Advanced Head and Neck Squamous Cell Carcinoma","volume":"38","author":"Papadimitrakopoulou","year":"2016","journal-title":"Head Neck"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1002\/cncr.32179","article-title":"A Randomized Phase 3 Trial Comparing Nimotuzumab Plus Cisplatin Chemoradiotherapy Versus Cisplatin Chemoradiotherapy Alone in Locally Advanced Head and Neck Cancer","volume":"125","author":"Patil","year":"2019","journal-title":"Cancer"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/0008-5472.CAN-14-2788","article-title":"CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis","volume":"75","author":"Jie","year":"2015","journal-title":"Cancer Res."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1038\/sj.onc.1209417","article-title":"Modulation of Cellular Radiation Responses by Histone Deacetylase Inhibitors","volume":"25","author":"Karagiannis","year":"2006","journal-title":"Oncogene"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/1078-0432.CCR-14-2820","article-title":"A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma","volume":"21","author":"Galloway","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Schoenwaelder, N., Salewski, I., Engel, N., Krause, M., Schneider, B., M\u00fcller, M., Riess, C., Lemcke, H., Skorska, A., and Grosse-Thie, C. (2021). The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cells\u2014A Systematic Analysis. Cancers, 13.","DOI":"10.3390\/cancers13102396"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.canlet.2021.04.004","article-title":"Dual Blockade of EGFR and CDK4\/6 Delays Head and Neck Squamous Cell Carcinoma Progression by Inducing Metabolic Rewiring","volume":"510","author":"Chaudhary","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.suronc.2019.09.001","article-title":"Progress in Targeted Therapeutic Drugs for Oral Squamous Cell Carcinoma","volume":"31","author":"Liu","year":"2019","journal-title":"Surg. Oncol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-Dependent Kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","article-title":"Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4\/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations","volume":"22","author":"Spring","year":"2017","journal-title":"Oncologist"},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"van Caloen, G., Schmitz, S., van Marcke, C., Caignet, X., Mendola, A., Ruys, S.P.D., Roger, P.P., Vertommen, D., and Machiels, J.P. (2021). Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4\/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck. Cancers, 13.","DOI":"10.3390\/cancers13061251"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1535-7163.MCT-19-0695","article-title":"Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck","volume":"19","author":"Schmitz","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fonc.2019.00155","article-title":"Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4\/6 Inhibitor Ribociclib and Cetuximab in Recurrent\/Metastatic P16-Negative Squamous Cell Carcinoma of the Head and Neck","volume":"9","author":"Seront","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.oraloncology.2016.05.011","article-title":"Phase I Trial of Palbociclib, a Selective Cyclin Dependent Kinase 4\/6 Inhibitor, in Combination with Cetuximab in Patients with Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma","volume":"58","author":"Michel","year":"2016","journal-title":"Oral Oncol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"105192","DOI":"10.1016\/j.oraloncology.2021.105192","article-title":"Palbociclib and Cetuximab Compared with Placebo and Cetuximab in Platinum-Resistant, Cetuximab-Na\u00efve, Human Papillomavirus-Unrelated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Double-Blind, Randomized, Phase 2 Trial","volume":"115","author":"Adkins","year":"2021","journal-title":"Oral Oncol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"105164","DOI":"10.1016\/j.oraloncology.2020.105164","article-title":"Palbociclib and Cetuximab in Cetuximab-Resistant Human Papillomavirus-Related Oropharynx Squamous-Cell Carcinoma: A Multicenter Phase 2 Trial","volume":"114","author":"Oppelt","year":"2021","journal-title":"Oral Oncol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13046-020-01763-z","article-title":"Therapeutic Evaluation of Palbociclib and Its Compatibility with Other Chemotherapies for Primary and Recurrent Nasopharyngeal Carcinoma","volume":"39","author":"Xue","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","article-title":"CDK4\/6 Inhibition in Cancer: Beyond Cell Cycle Arrest","volume":"28","author":"Goel","year":"2018","journal-title":"Trends Cell Biol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1007\/s10637-020-00898-2","article-title":"A Multi-Center Phase II Trial Evaluating the Efficacy of Palbociclib in Combination with Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","volume":"38","author":"Swiecicki","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41419-019-2098-8","article-title":"Cisplatin Exposure Causes C-Myc-Dependent Resistance to CDK4\/6 Inhibition in HPV-Negative Head and Neck Squamous Cell Carcinoma","volume":"10","author":"Robinson","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"696","DOI":"10.18632\/oncotarget.2673","article-title":"Cyclin E1 and RTK\/RAS Signaling Drive CDK Inhibitor Resistance via Activation of E2F and ETS","volume":"6","author":"Aspuria","year":"2015","journal-title":"Oncotarget"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"264","DOI":"10.20892\/j.issn.2095-3941.2018.0257","article-title":"Effects of Palbociclib in Oral Squamous Cell Carcinoma and the Role of PIK3CA in Conferring Resistance","volume":"16","author":"Zainal","year":"2019","journal-title":"Cancer Biol. Med."},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Kostopoulou, O.N., Zupancic, M., Pont, M., Papin, E., Lukoseviciute, M., Mikelarena, B.A., Holzhauser, S., and Dalianis, T. (2022). Targeted Therapy of HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy between CDK4\/6, PI3K and Sometimes FGFR Inhibitors, but Rarely between PARP and WEE1 Inhibitors. Viruses, 14.","DOI":"10.3390\/v14071372"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3389\/fonc.2021.640490","article-title":"Targeted Therapy With PI3K and FGFR Inhibitors on Human Papillomavirus Positive and Negative Tonsillar and Base of Tongue Cancer Lines With and Without Corresponding Mutations","volume":"11","author":"Holzhauser","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","article-title":"Myelopreservation with the CDK4\/6 Inhibitor Trilaciclib in Patients with Small-Cell Lung Cancer Receiving First-Line Chemotherapy: A Phase Ib\/Randomized Phase II Trial","volume":"30","author":"Weiss","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Shrivastava, N., Chavez, C.G., Li, D., Mehta, V., Thomas, C., Fulcher, C.D., Kawachi, N., Bottalico, D.M., Prystowsky, M.B., and Basu, I. (2023). CDK4\/6 Inhibition Induces Senescence and Enhances Radiation Response by Disabling DNA Damage Repair in Oral Cavity Squamous Cell Carcinoma. Cancers, 15.","DOI":"10.3390\/cancers15072005"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"8368","DOI":"10.1002\/jcb.26920","article-title":"EGFR-Mediated Signaling Pathway Influences the Sensitivity of Oral Squamous Cell Carcinoma to JQ1","volume":"119","author":"Liu","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Hajmirza, A., Emadali, A., Gauthier, A., Casasnovas, O., Gressin, R., and Callanan, M. (2018). BET Family Protein BRD4: An Emerging Actor in NF\u03baB Signaling in Inflammation and Cancer. Biomedicines, 6.","DOI":"10.3390\/biomedicines6010016"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and Cancer: Going beyond Transcriptional Regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jop.12784","article-title":"JQ1 and PI3K Inhibition Synergistically Reduce Salivary Adenoid Cystic Carcinoma Malignancy by Targeting the C-Myc and EGFR Signaling Pathways","volume":"48","author":"Liu","year":"2019","journal-title":"J. Oral Pathol. Med."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1038\/oncsis.2016.86","article-title":"Inhibition of the Integrin\/FAK Signaling Axis and c-Myc Synergistically Disrupts Ovarian Cancer Malignancy","volume":"6","author":"Xu","year":"2017","journal-title":"Oncogenesis"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature14898","article-title":"Transcriptional Plasticity Promotes Primary and Acquired Resistance to BET Inhibition","volume":"525","author":"Rathert","year":"2015","journal-title":"Nature"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ccell.2018.11.005","article-title":"Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling","volume":"34","author":"Iniguez","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.canlet.2019.11.027","article-title":"Combinational Therapeutic Targeting of BRD4 and CDK7 Synergistically Induces Anticancer Effects in Head and Neck Squamous Cell Carcinoma","volume":"469","author":"Zhang","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41594-020-0488-3","article-title":"Super-Enhancer Switching Drives a Burst in Gene Expression at the Mitosis-to-Meiosis Transition","volume":"27","author":"Maezawa","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"e12779","DOI":"10.1111\/jpi.12779","article-title":"Melatonin and Verteporfin Synergistically Suppress the Growth and Stemness of Head and Neck Squamous Cell Carcinoma through the Regulation of Mitochondrial Dynamics","volume":"72","author":"Shin","year":"2022","journal-title":"J. Pineal Res."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1172\/JCI87631","article-title":"FOXM1 Is a Critical Driver of Lung Fibroblast Activation and Fibrogenesis","volume":"128","author":"Penke","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/jop.12906","article-title":"Co-Inhibition of BET Proteins and PD-L1 as a Potential Therapy for OSCC through Synergistic Inhibition of FOXM1 and PD-L1 Expressions","volume":"48","author":"Wang","year":"2019","journal-title":"J. Oral Pathol. Med."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12519-019-00271-1","article-title":"Forkhead Box M1 Transcription Factor: A Novel Target for Pulmonary Arterial Hypertension Therapy","volume":"16","author":"Gu","year":"2020","journal-title":"World J. Pediatr."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.2147\/OTT.S105862","article-title":"PD-L1 Expression in Human Cancers and Its Association with Clinical Outcomes","volume":"9","author":"Wang","year":"2016","journal-title":"Onco. Targets. Ther."},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Li, B., Jin, J., Guo, D., Tao, Z., and Hu, X. (2023). Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials. Cancers, 15.","DOI":"10.3390\/cancers15102858"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune Checkpoint Inhibitors: Recent Progress and Potential Biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"e003476","DOI":"10.1136\/jitc-2021-003476","article-title":"Antitumor Immune Effects of Preoperative Sitravatinib and Nivolumab in Oral Cavity Cancer: SNOW Window-of-Opportunity Study","volume":"9","author":"Oliva","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"e004424","DOI":"10.1136\/jitc-2021-004424","article-title":"Dual Checkpoint Targeting of B7-H3 and PD-1 with Enoblituzumab and Pembrolizumab in Advanced Solid Tumors: Interim Results from a Multicenter Phase I\/II Trial","volume":"10","author":"Aggarwal","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat. Med."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial","volume":"6","author":"Schoenfeld","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1200\/JCO.22.00332","article-title":"Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent\/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651","volume":"41","author":"Haddad","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.annonc.2022.12.008","article-title":"Durvalumab with or without Tremelimumab versus the EXTREME Regimen as First-Line Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: KESTREL, a Randomized, Open-Label, Phase III Study","volume":"34","author":"Psyrri","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","article-title":"Durvalumab with or without Tremelimumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: EAGLE, a Randomized, Open-Label Phase III Study","volume":"31","author":"Ferris","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-15-0827","article-title":"Bruton Tyrosine Kinase\u2013Dependent Immune Cell Cross-Talk Drives Pancreas Cancer","volume":"6","author":"Gunderson","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1158\/1078-0432.CCR-21-2547","article-title":"Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study","volume":"28","author":"Taylor","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3389\/fimmu.2019.00604","article-title":"Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect","volume":"10","author":"Suek","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1078-0432.CCR-21-1411","article-title":"Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Na\u00efve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial","volume":"28","author":"Cohen","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/14712598.2020.1688298","article-title":"NK Cell-Based Therapeutics for Lung Cancer","volume":"20","author":"Pockley","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/1078-0432.CCR-21-2635","article-title":"Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck","volume":"28","author":"Hanna","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1038\/s41467-022-33080-8","article-title":"A Pilot Study of Neoadjuvant Combination of Anti-PD-1 Camrelizumab and VEGFR2 Inhibitor Apatinib for Locally Advanced Resectable Oral Squamous Cell Carcinoma","volume":"13","author":"Ju","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_259","doi-asserted-by":"crossref","unstructured":"Catalano, S., Panza, S., Augimeri, G., Giordano, C., Malivindi, R., Gelsomino, L., Marsico, S., Gy\u0151rffy, B., Bonofiglio, D., and And\u00f2, S. (2019). Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression. Cancers, 11.","DOI":"10.3390\/cancers11111740"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1158\/1078-0432.CCR-15-1900","article-title":"Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy","volume":"22","author":"Catalano","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1038\/s41467-020-17028-4","article-title":"Phosphodiesterase-5 Inhibitors Use and Risk for Mortality and Metastases among Male Patients with Colorectal Cancer","volume":"11","author":"Huang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_262","first-page":"3311","article-title":"Sildenafil Inhibits the Growth of Human Colorectal Cancer in Vitro and in Vivo","volume":"5","author":"Mei","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/1078-0432.CCR-21-1816","article-title":"Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma","volume":"28","author":"Luginbuhl","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"105634","DOI":"10.1016\/j.oraloncology.2021.105634","article-title":"Pembrolizumab plus Docetaxel for the Treatment of Recurrent\/Metastatic Head and Neck Cancer: A Prospective Phase I\/II Study","volume":"124","author":"Fuereder","year":"2022","journal-title":"Oral Oncol."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-22-0666","article-title":"Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_266","doi-asserted-by":"crossref","unstructured":"Li, X., Fang, Q., Du, W., Zhang, X., Dai, L., and Qiao, Y. (2021). Induction Chemotherapy Combined with Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08373-8"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s13046-022-02510-2","article-title":"Neoadjuvant Toripalimab Combined with Gemcitabine and Cisplatin in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (NeoTGP01): An Open Label, Single-Arm, Phase Ib Clinical Trial","volume":"41","author":"Huang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study","volume":"41","author":"Harrington","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus Standard-of-Care Chemoradiotherapy versus Chemoradiotherapy Alone in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase 3 Trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"S1310","DOI":"10.1016\/j.annonc.2021.08.2112","article-title":"LBA35 Avelumab-Cetuximab-Radiotherapy versus Standards of Care in Patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LA-SCCHN): Randomized Phase III GORTEC-REACH Trial","volume":"32","author":"Bourhis","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-21-3849","article-title":"Phase II Multi-Institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinoma","volume":"28","author":"Chung","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"106219","DOI":"10.1016\/j.oraloncology.2022.106219","article-title":"A Phase I Study of Avelumab, Palbociclib, and Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","volume":"135","author":"Dennis","year":"2022","journal-title":"Oral Oncol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(21)00136-4","article-title":"Pembrolizumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-Label, Multi-Arm, Non-Randomised, Multicentre, Phase 2 Trial","volume":"22","author":"Sacco","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1158\/1078-0432.CCR-21-3025","article-title":"Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis","volume":"28","author":"Kao","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_275","doi-asserted-by":"crossref","unstructured":"Chung, C.H., Bonomi, M., Steuer, C.E., Li, J., Bhateja, P., Johnson, M., Masannat, J., Song, F., Hernandez-prera, J.C., and Wenig, B.M. (2021). Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and \/ or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I \/ II Study. Cancers, 13.","DOI":"10.3390\/cancers13051180"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","article-title":"A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer","volume":"26","author":"Rodriguez","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"111092","DOI":"10.1016\/j.fct.2019.111092","article-title":"NDAT Suppresses Pro-Inflammatory Gene Expression to Enhance Resveratrol-Induced Anti-Proliferation in Oral Cancer Cells","volume":"136","author":"Ho","year":"2020","journal-title":"Food Chem. Toxicol."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"31169","DOI":"10.18632\/oncotarget.16099","article-title":"Depth of Response Is a Significant Predictor for Long-Term Outcome in Advanced Gastric Cancer Patients Treated with Trastuzumab","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fendo.2017.00261","article-title":"Macropinocytosis: A Metabolic Adaptation to Nutrient Stress in Cancer","volume":"8","author":"Recouvreux","year":"2017","journal-title":"Front. Endocrinol."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"112661","DOI":"10.1016\/j.biopha.2022.112661","article-title":"Regorafenib Enhances Antitumor Immune Efficacy of Anti-PD-L1 Immunotherapy on Oral Squamous Cell Carcinoma","volume":"147","author":"Chiang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"100877","DOI":"10.1016\/j.esmoop.2023.100877","article-title":"Safety and Efficacy of Cobimetinib plus Atezolizumab in Patients with Solid Tumors: A Phase II, Open-Label, Multicenter, Multicohort Study","volume":"8","author":"Sherman","year":"2023","journal-title":"ESMO Open"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"P303","DOI":"10.1186\/2051-1426-3-S2-P303","article-title":"Improved Anti-Tumor Immunity and Efficacy upon Combination of the IDO1 Inhibitor GDC-0919 with Anti-PD-L1 Blockade versus Anti-PD-L1 Alone in Preclinical Tumor Models","volume":"3","author":"Spahn","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/bs.ircmb.2017.07.004","article-title":"Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer","volume":"Volume 336","author":"Prendergast","year":"2018","journal-title":"International Review of Cell and Molecular Biology"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors","volume":"25","author":"Jung","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I\/II Trial (ECHO-202\/KEYNOTE-037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"151075","DOI":"10.1016\/j.ejcb.2020.151075","article-title":"Microtubule-Targeting Agents and Their Impact on Cancer Treatment","volume":"99","year":"2020","journal-title":"Eur. J. Cell Biol."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13058-022-01506-2","article-title":"Microtubule Disruption Reduces Metastasis More Effectively than Primary Tumor Growth","volume":"24","author":"Thompson","year":"2022","journal-title":"Breast Cancer Res."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00280-015-2903-8","article-title":"Antimitotic Drugs in the Treatment of Cancer","volume":"76","author":"Visagie","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3253","article-title":"Microtubule-Binding Agents: A Dynamic Field of Cancer Therapeutics","volume":"9","author":"Dumontet","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_290","doi-asserted-by":"crossref","unstructured":"Novais, P., Silva, P.M.A., Amorim, I., and Bousbaa, H. (2021). Second-Generation Antimitotics in Cancer Clinical Trials. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13071011"},{"key":"ref_291","first-page":"1087","article-title":"Inhibition of Phosphatidylinositol 3\u2032-Kinase Increases Efficacy of Paclitaxel in in Vitro and in Vivo Ovarian Cancer Models","volume":"62","author":"Hu","year":"2002","journal-title":"Cancer Res."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(17)30064-5","article-title":"Buparlisib and Paclitaxel in Patients with Platinum-Pretreated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (BERIL-1): A Randomised, Double-Blind, Placebo-Controlled Phase 2 Trial","volume":"18","author":"Faivre","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.oraloncology.2014.12.013","article-title":"A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Head and Neck Squamous Cell Cancer","volume":"51","author":"Jimeno","year":"2015","journal-title":"Oral Oncol."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/hed.23522","article-title":"Phase II Trial of Biweekly Gemcitabine and Paclitaxel with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0329","volume":"36","author":"Malhotra","year":"2014","journal-title":"Head Neck"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"569","DOI":"10.4143\/crt.2016.289","article-title":"An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer","volume":"49","author":"Park","year":"2017","journal-title":"Cancer Res. Treat."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"751-e231","DOI":"10.1634\/theoncologist.2019-0070","article-title":"A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","volume":"24","author":"Keam","year":"2019","journal-title":"Oncologist"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1093\/annonc\/mdx346","article-title":"A Phase II Study of Temsirolimus Added to Low-Dose Weekly Carboplatin and Paclitaxel for Patients with Recurrent and\/or Metastatic (R\/M) Head and Neck Squamous Cell Carcinoma (HNSCC)","volume":"28","author":"Dunn","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2019.08.018","article-title":"Cetuximab, Fluorouracil and Cisplatin with or without Docetaxel for Patients with Recurrent and\/or Metastatic Squamous Cell Carcinoma of the Head and Neck (CeFCiD): An Open-Label Phase II Randomised Trial (AIO\/IAG-KHT Trial 1108)","volume":"122","author":"Klinghammer","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1158\/1078-0432.CCR-17-3796","article-title":"A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma","volume":"24","author":"Rodriguez","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2016.67.5991","article-title":"Phase I Study Evaluating WEE1 Inhibitor AZD1775 as Monotherapy and in Combination with Gemcitabine, Cisplatin, or Carboplatin in Patients with Advanced Solid Tumors","volume":"34","author":"Leijen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1158\/2159-8290.CD-11-0320","article-title":"Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1","volume":"2","author":"Aarts","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1534\/genetics.113.156281","article-title":"Dual Phosphorylation of Cdk1 Coordinates Cell Proliferation with Key Developmental Processes in Drosophila","volume":"196","author":"Ayeni","year":"2014","journal-title":"Genetics"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10555-018-9728-y","article-title":"Developing TRAIL\/TRAIL Death Receptor-Based Cancer Therapies","volume":"37","author":"Yuan","year":"2018","journal-title":"Cancer Metastasis Rev."},{"key":"ref_304","first-page":"3439","article-title":"Synergism between \u03b1-Mangostin and TRAIL Induces Apoptosis in Squamous Cell Carcinoma of the Oral Cavity through the Mitochondrial Pathway","volume":"38","author":"Fukuda","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1016\/j.biomaterials.2011.01.054","article-title":"Improved Biological Half-Life and Anti-Tumor Activity of TNF-Related Apoptosis-Inducing Ligand (TRAIL) Using PEG-Exposed Nanoparticles","volume":"32","author":"Lim","year":"2011","journal-title":"Biomaterials"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-13-0516","article-title":"PARP-1 Regulates Resistance of Pancreatic Cancer to Trail Therapy","volume":"19","author":"Yuan","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"25828","DOI":"10.18632\/oncotarget.4558","article-title":"Understanding of Tolerance in TRAIL-Induced Apoptosis and Cancelation of Its Machinery by \u03b1-Mangostin, a Xanthone Derivative","volume":"6","author":"Kumazaki","year":"2015","journal-title":"Oncotarget"},{"key":"ref_308","first-page":"1731","article-title":"Differential Augmentative Effects of Buthionine Sulfoximine and Ascorbic Acid in As2O3-Induced Ovarian Cancer Cell Death: Oxidative Stress-Independent and -Dependent Cytotoxic Potentiation","volume":"38","author":"Ong","year":"2011","journal-title":"Int. J. Oncol."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.freeradbiomed.2011.03.007","article-title":"Pharmacologic Ascorbate Synergizes with Gemcitabine in Preclinical Models of Pancreatic Cancer","volume":"50","author":"Espey","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"11105","DOI":"10.1073\/pnas.0804226105","article-title":"Pharmacologic Doses of Ascorbate Act as a Prooxidant and Decrease Growth of Aggressive Tumor Xenografts in Mice","volume":"105","author":"Chen","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"7689045","DOI":"10.1155\/2021\/7689045","article-title":"A Marine Terpenoid, Heteronemin, Induces Both the Apoptosis and Ferroptosis of Hepatocellular Carcinoma Cells and Involves the ROS and MAPK Pathways","volume":"2021","author":"Chang","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1002\/pros.23230","article-title":"Heteronemin Is a Novel C-Met\/STAT3 Inhibitor Against Advanced Prostate Cancer Cells","volume":"76","author":"Wu","year":"2016","journal-title":"Prostate"},{"key":"ref_313","doi-asserted-by":"crossref","unstructured":"Lin, H.Y., Tey, S.L., Ho, Y., Chin, Y.T., Wang, K., Whang-Peng, J., Shih, Y.J., Chen, Y.R., Yang, Y.N., and Chen, Y.C. (2018). Heteronemin Induces Anti-Proliferation in Cholangiocarcinoma Cells via Inhibiting TGF-\u03b2 Pathway. Mar. Drugs, 16.","DOI":"10.3390\/md16120489"},{"key":"ref_314","doi-asserted-by":"crossref","unstructured":"Britt, E.L., Raman, S., Leek, K., Sheehy, C.H., Kim, S.W., and Harada, H. (2019). Combination of Fenretinide and ABT-263 Induces Apoptosis through NOXA for Head and Neck Squamous Cell Carcinoma Treatment. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0219398"},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1158\/0008-5472.CAN-16-2098","article-title":"The P53\/P21 Complex Regulates Cancer Cell Invasion and Apoptosis by Targeting Bcl-2 Family Proteins","volume":"77","author":"Kim","year":"2017","journal-title":"Cancer Res."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.2147\/OTT.S146228","article-title":"MCL-1 Inhibition in Cancer Treatment","volume":"11","author":"Xiang","year":"2018","journal-title":"Onco. Targets. Ther."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/jcp.25293","article-title":"A NOXA\/MCL-1 Imbalance Underlies Chemoresistance of Malignant Rhabdoid Tumor Cells","volume":"231","author":"Ouchi","year":"2016","journal-title":"J. Cell. Physiol."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"494","DOI":"10.18632\/oncotarget.26563","article-title":"Optimal Targeting of BCL-Family Proteins in Head and Neck Squamous Cell Carcinoma Requires Inhibition of Both BCL-XL and MCL-1","volume":"10","author":"Ow","year":"2019","journal-title":"Oncotarget"},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1007\/s10637-019-00886-1","article-title":"W941, a New PI3K Inhibitor, Exhibits Preferable Anti-Proliferative Activities against Nonsmall Cell Lung Cancer with Autophagy Inhibitors","volume":"38","author":"Liang","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1078-0432.CCR-12-3114","article-title":"Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363","volume":"19","author":"Lamoureux","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_321","doi-asserted-by":"crossref","unstructured":"Bernard, M., Cardin, G.B., Cahuzac, M., Ayad, T., Bissada, E., Guertin, L., Bahig, H., Nguyen-Tan, P.F., Filion, E., and Ballivy, O. (2020). Dual Inhibition of Autophagy and Pi3k\/Akt\/Mtor Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12092371"},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"10826","DOI":"10.1038\/s41598-021-90289-1","article-title":"IGF1R and Src Inhibition Induce Synergistic Cytotoxicity in HNSCC through Inhibition of FAK","volume":"11","author":"Lehman","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"105173","DOI":"10.1016\/j.oraloncology.2020.105173","article-title":"Nanoparticle Albumin-Bound Paclitaxel with Cetuximab and Carboplatin as First-Line Therapy for Recurrent or Metastatic Head and Neck Cancer: A Single-Arm, Multicenter, Phase 2 Trial","volume":"115","author":"Adkins","year":"2021","journal-title":"Oral Oncol."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1158\/1078-0432.CCR-04-0703","article-title":"Chemoresistance: Impact of Nuclear Factor (NF)-\u039aB Inhibition by Small Interfering RNA","volume":"10","author":"Veiby","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s10637-010-9439-x","article-title":"Simvastatin Enhances Irinotecan-Induced Apoptosis in Human Non-Small Cell Lung Cancer Cells by Inhibition of Proteasome Activity","volume":"29","author":"Park","year":"2011","journal-title":"Investig. New Drugs"},{"key":"ref_326","first-page":"942","article-title":"Phase II 2-Arm Trial of the Proteasome Inhibitor, PS-341 (Bortezomib) in Combination with Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients with Locally Recurrent or Metastatic Squamous Cell Carcinoma","volume":"341","author":"Gilbert","year":"2012","journal-title":"Head Neck"},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.ejca.2015.06.115","article-title":"Results of a Phase 1 Trial Combining Ridaforolimus and MK-0752 in Patients with Advanced Solid Tumours","volume":"51","author":"Munster","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcdb.2020.01.005","article-title":"Unraveling the Complexity of \u03b3-Secretase","volume":"105","author":"Wolfe","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"e1126037","DOI":"10.1080\/2162402X.2015.1126037","article-title":"Motolimod Effectively Drives Immune Activation in Advanced Cancer Patients","volume":"5","author":"Dietsch","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jamaoncol.2018.1888","article-title":"Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck the ACTIVE8 Randomized Clinical Trial","volume":"4","author":"Ferris","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1038\/onc.2015.129","article-title":"Lysine-Specific Demethylase 1 Promotes the Stemness and Chemoresistance of Lgr5+ Liver Cancer Initiating Cells by Suppressing Negative Regulators of \u03b2-Catenin Signaling","volume":"34","author":"Lei","year":"2015","journal-title":"Oncogene"},{"key":"ref_332","doi-asserted-by":"crossref","unstructured":"Verigos, J., Karakaidos, P., Kordias, D., Papoudou-Bai, A., Evangelou, Z., Harissis, H.V., Klinakis, A., and Magklara, A. (2019). The Histone Demethylase LSD1\/\u039aDM1A Mediates Chemoresistance in Breast Cancer via Regulation of a Stem Cell Program. Cancers, 11.","DOI":"10.3390\/cancers11101585"},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","article-title":"LSD1 Ablation Stimulates Anti-Tumor Immunity and Enables Checkpoint Blockade","volume":"174","author":"Sheng","year":"2018","journal-title":"Cell"},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/1541-7786.MCR-21-0310","article-title":"Inhibition of LSD1 Attenuates Oral Cancer Development and Promotes Therapeutic Efficacy of Immune Checkpoint Blockade and YAP\/TAZ Inhibition","volume":"20","author":"Alhousami","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ddr.22045","article-title":"PX-12 Synergistically Enhances the Therapeutic Efficacy of Vorinostat under Hypoxic Tumor Microenvironment in Oral Squamous Cell Carcinoma in Vitro","volume":"84","author":"Akhlaq","year":"2023","journal-title":"Drug Dev. Res."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00280-019-03912-4","article-title":"The Thioredoxin System and Cancer Therapy: A Review","volume":"84","author":"Mohammadi","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pharmthera.2010.04.004","article-title":"Anti-Oxidative, Anti-Cancer and Anti-Inflammatory Actions by Thioredoxin 1 and Thioredoxin-Binding Protein-2","volume":"127","author":"Watanabe","year":"2010","journal-title":"Pharmacol. Ther."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/6\/1653\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:48:05Z","timestamp":1760125685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/6\/1653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,4]]},"references-count":337,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["pharmaceutics15061653"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15061653","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,4]]}}}